Phlow Announces $35M in Series B Funding to Improve the U.S. Medicine Supply Chain

URLhttps://www.contractpharma.com/contents/view_break
SourceContract Pharma
Date Published04/06/2023
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Phlow Corp.
Type of work Manufacturing
Reshoring category:Reshoring
Year reshoring announced:2023
Domestically, the work will be done:In-house
Capital investment ($):36
City reshored to:Petersburg
State(s) reshored to:VA
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredpharmaceuticals
What non-domestic negative factors made offshoring less attractive?Quality/rework/warranty, Supply chain interruption risk/Natural disaster risk/Political instability , Total cost
What domestic positive factors made reshoring more attractive?Impact on domestic economy, Lead time/Time to market, Lean/other business process improvement techniques
Find Reshoring Articles